Medpace Holdings (NASDAQ: MEDP) will announce its third quarter 2026 financial results after market close on Wednesday, October 21, 2026. The clinical contract research organization plans to discuss these figures with investors during a conference call the following morning.

Conference call details

The earnings call is scheduled for Thursday, October 22, 2026, at 9:00 am ET. Participants are advised to register in advance to receive dial-in numbers and unique PINs via confirmation email. Joining ten minutes prior to the start time is recommended but not mandatory.

For those preferring digital access, a webcast will be available through the Investors section of Medpace’s website. A replay of the session will be posted approximately one hour after the call concludes. Additionally, a supplemental slide presentation will be accessible on the same site before the event begins.

Company profile

Medpace operates as a global, full-service clinical contract research organization (CRO) serving biotechnology, pharmaceutical, and medical device industries. The company provides Phase I-IV clinical development services with a focus on oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral therapies.

Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,500 people across 46 countries as of June 30, 2026.

Medpace Holdings (NASDAQ: MEDP) has delivered an average annual return of 26.82% over the past five years, outperforming the broader market by 15.31% on an annualized basis.

The clinical research organization currently holds a market capitalization of $16.58 billion. The stock’s performance highlights the impact of compounded growth over a multi-year horizon.

Investment Performance

An investor who purchased $100 of Medpace Holdings stock five years ago would see that position valued at $320.04 today, based on a share price of $594.10 at the time of writing.

What the Numbers Show

The data illustrates the divergence between absolute price appreciation and relative market performance. While the stock generated a total return that tripled the initial investment ($100 to $320.04), the key differentiator is the 15.31% annualized excess return over the market benchmark. This suggests that Medpace’s valuation expansion was driven by factors specific to the company or its sector rather than broad market beta alone.